Fecal transplant plus cancer immunotherapy for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether giving a fecal microbiota transplant (a stool-based sample from a carefully screened donor) alongside immune checkpoint inhibitors can improve outcomes in people with lung cancer. It aims to change the gut bacteria to help the immune system work better against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (18+) with a confirmed cancer diagnosis, specifically planning lung cancer treatment.
- You plan to start chemotherapy and/or immune checkpoint inhibitors and/or targeted therapy.
- Your current health status should be fairly good (ECOG 0 to 2).
- Do not have a serious allergy, or any allergy that would be a problem with omeprazole (a common stomach medicine used in studies).
- Do not take probiotics or other pre-/probiotics in the 4 weeks before enrollment.
- You must be able to safely swallow the study capsules and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a fecal microbiota transplant (a stool transplant from a healthy donor or someone who responded well to immunotherapy) together with the immunotherapy drug tislelizumab can help people with advanced or metastatic non-small cell lung cancer (NSCLC). It's for patients whose cancer grew after prior immunotherapy.
This trial tests whether taking an oral fecal transplant (MaaT033) along with the immunotherapy drug cemiplimab can help people whose lung cancer stopped responding after antibiotics. It's for people with advanced non-small cell lung cancer whose cancer got worse after standard immunotherapy.
This trial tests a combination of fecal microbiota transplantation (FMT), immunotherapy, and chemotherapy as a first treatment for advanced non-small cell lung cancer that does not have a driver gene mutation. The goal is to see if adding FMT can help the immune system fight the cancer better.
This trial tests if a fecal transplant from immunotherapy responders can help treat stage II-III non-small cell lung cancer patients who haven't had treatment yet.
This trial tests whether combining fecal microbiota transplantation (FMT) with chemotherapy, radiotherapy, and immunotherapy before surgery can help shrink locally advanced rectal cancer that is MSS/pMMR. FMT involves transferring healthy donor stool to restore gut bacteria, which may boost treatment response.
This trial tests whether the bacteria in your gut (microbiome) can affect how well immunotherapy works for lung cancer that can be surgically removed. You may receive immunotherapy or chemotherapy before surgery to shrink the tumor.
Hear when a new Metastatic Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.